UroGen Pharma (NASDAQ:URGN) Downgraded by Zacks Investment Research to “Sell”

UroGen Pharma (NASDAQ:URGNGet Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Friday, Zacks.com reports.

According to Zacks, “UroGen Pharma Ltd. is a clinical stage biopharmaceutical company. It focused on developing urological pathologies with a focus on uro-oncology. The company’s product candidates include MitoGel and VesiGel which are in clinical trial stage. Its platform technologies include: RTGel and Immunotherapy. UroGen Pharma Ltd. is based in Ra’anana, Israel. “

Several other research firms have also recently commented on URGN. The Goldman Sachs Group raised their price target on shares of UroGen Pharma from $10.00 to $11.00 and gave the stock a “neutral” rating in a report on Tuesday, March 22nd. HC Wainwright lowered their price target on shares of UroGen Pharma from $34.00 to $26.00 in a report on Tuesday, March 22nd. Finally, Berenberg Bank began coverage on shares of UroGen Pharma in a research note on Wednesday, April 27th. They issued a “buy” rating and a $20.00 price target on the stock.

URGN stock opened at $6.32 on Friday. UroGen Pharma has a one year low of $5.61 and a one year high of $19.66. The firm has a 50-day moving average of $7.86 and a two-hundred day moving average of $9.86.

UroGen Pharma (NASDAQ:URGNGet Rating) last released its quarterly earnings results on Monday, March 21st. The company reported ($1.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.18) by ($0.09). UroGen Pharma had a negative net margin of 230.67% and a negative return on equity of 256.66%. The firm had revenue of $16.17 million for the quarter, compared to analyst estimates of $16.15 million. Sell-side analysts predict that UroGen Pharma will post -4.9 EPS for the current year.

A number of institutional investors have recently bought and sold shares of the business. Citigroup Inc. boosted its position in UroGen Pharma by 49.4% during the third quarter. Citigroup Inc. now owns 3,443 shares of the company’s stock worth $58,000 after purchasing an additional 1,138 shares during the period. Sterling Investment Advisors Ltd. acquired a new stake in shares of UroGen Pharma in the third quarter worth $34,000. BNP Paribas Arbitrage SA boosted its holdings in shares of UroGen Pharma by 359.8% during the 3rd quarter. BNP Paribas Arbitrage SA now owns 3,559 shares of the company’s stock worth $60,000 after buying an additional 2,785 shares during the period. Parallel Advisors LLC grew its stake in UroGen Pharma by 6,383.0% in the 1st quarter. Parallel Advisors LLC now owns 3,047 shares of the company’s stock valued at $28,000 after buying an additional 3,000 shares during the last quarter. Finally, Denali Advisors LLC bought a new position in UroGen Pharma in the 1st quarter worth $36,000.

UroGen Pharma Company Profile (Get Rating)

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.

See Also

Get a free copy of the Zacks research report on UroGen Pharma (URGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for UroGen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UroGen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.